Zambia to Launch Biannual Injectable ARV in 2026
By Cindy Mulomba
The Ministry of Health is preparing to introduce a new injectable antiretroviral (ARV) drug that will require just two doses per year, marking a major step forward in improving treatment adherence among people living with HIV.
According to Dr. Chimika Phiri, HIV Prevention Lead at the Ministry, the new long-acting injectable could be rolled out as early as January 2026, with the initial phase targeting patients on third-line treatment regimens who currently rely on multiple daily tablets.
Dr. Phiri emphasized that this innovation reflects the government’s commitment to embracing new technologies and expanding treatment options. He noted that injectable ARVs offer greater privacy and discretion, helping individuals manage their health without fear of stigma.
Zambia has already introduced Cabotegravir, an injectable pre-exposure prophylaxis (PrEP) administered every two months, making it one of the first countries globally to roll out this prevention method outside of research settings2.
The upcoming biannual injectable ARV is expected to further strengthen Zambia’s efforts to achieve viral suppression, reduce pill fatigue, and enhance quality of life for patients.
#HIVTreatmentZambia
#InjectableARV
(file photo)
